Clinical Observation of Atorvastatin Combined with Acipimox for Combined Hyperlipidemia

OBJECTIVE:To observe clinical efficacy of atorvastatin combined with acipimox for combined hyperlipidemia. METHODS:150 cases of combined hyperlipidemia were randomly divided into atorvastatin group,acipimox group and combined treatment group(atorvastatin+acipimox). Atorvastatin group was given atorvastatin 20 mg orally every night;acipimox group received acipimox 250 mg orally every morning and night;combined treatment group was treated with atorvastatin and acipimox with the same usage and dosage of atorvastatin group and atorvastatin group. All patients in 3 groups were treated for 8 weeks. Clinical efficacies of all patients were evaluated. The changes of the main lipid parameters,such as TC,TG,LDL and HDL,were detected before and after treatment;the compliance rate was calculated. Hepatic function,renal function,serum creatinine kinase(CK),creatine phosphate(CrP)and side effects were also observed and analyzed in this study. RESULTS:Total effective rate of combination group was significantly higher than the atorvastatin group and acipimox group(P0.05). The levels of TC,TG and LDL in 3 groups were significantly lower than before;there was statistical significance(P0.05). The HDL of acipimox group and combined treatment group was significantly higher than before,there was statistical significance(P0.05). After treatment,the levels of TG and LDL in combined treatment group were significantly lower than in atorvastatin group and acipimox group;the compliance rates of TC,TG,LDL and HDL in combined treatment group were significantly higher than those of atorvastatin group and acipimox group;there was statistical significance(P0.05). There was no statistical significance in the incidence of ADR among 3 groups(P0.05). CONCLUSIONS:Atorvastation combined with acipimox is safe and effective for combined hyperlipidemia.